Vivoryon also presented a poster at the World Congress of Nephrology (WCN) in Yokohama, Japan on March 28, 2026, providing an update on the growing body of evidence validating glutaminyl cyclases ...

Group sales were +6% at constant exchange rates (CER)1, -5% when reported in CHF and +9% in USD2, in the first three months, ...

The new GLB is a significant step forward over its EQB predecessor, offering seven-seat practicality, cutting-edge technology ...

Tuesday, May 6, 2025 at 8:30 a.m. ET Michael Stein said, "the year over year comparative results for our retail energy ...

And last week, MGIC paid a $400 million dividend to the holding company. The dividend from MGIC to the holding company ...

I'd like to welcome you to IBM's First Quarter 2026 Earnings Presentation. I'm Olympia McNerney, and I'm here today with Arvind Krishna, IBM's Chairman, President and Chief Executive Officer; and Jim ...

There’s a general consensus that too much screen time is bad for kids. But what happens when everything in modern society is ...

Thank you for standing by for New Oriental's FY 2026 Third Quarter Results Earnings Conference Call. [Operator Instructions] Today's conference is being recorded. If you have any objections, you may ...

Group sales were +6% at constant exchange rates (CER) 1, -5% when reported in CHF and +9% in USD 2, in the first three months, driven by high demand for our innovative medicines and diagnostics.

ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease ...

Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability scores, and eliminated the need for chronic immunotherapies -- outcomes not previously observed in SPS ...

Single-dose of miv-cel achieved robust and durable improvements in mobility, reversed disability scores, and eliminated the need for chronic ...